Endothelin antagonism for patients with chronic kidney disease: Still a hope for the future

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Schneider, Markus P ^a   Mann, Johannes F ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Munich General Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AVOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; LISINOPRIL; SITAXSENTAN;

ARTICLE; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; DRUG EFFECT; EXPERIMENTAL STUDY; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY INNER MEDULLA; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM EXCRETION; UPREGULATION;

ANIMALS; ENDOTHELINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84893865833     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft339     Document Type: Review

References (52)

1. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415
2. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-2867
3. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007; 47: 731-759
4. Kisanuki YY, Emoto N, Ohuchi T et al. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 2010; 56: 121-128
5. Haynes WG, Ferro CJ, O'Kane KP et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-1870
6. Kohan DE. Endothelin synthesis by rabbit renal tubule cells. Am J Physiol 1991; 261: F221-F226
7. Kohan DE, Hughes AK, Perkins SL. Characterization of endothelin receptors in the inner medullary collecting duct of the rat. J Biol Chem 1992; 267: 12336-12340
8. Silldorff EP, Yang S, Pallone TL. Prostaglandin E2 abrogates endothelininduced vasoconstriction in renal outer medullary descending vasa recta of the rat. J Clin Invest 1995; 95: 2734-2740
9. Ahn D, Ge Y, Stricklett PK et al. Collecting duct-specific knockout of endothelin- 1 causes hypertension and sodium retention. J Clin Invest 2004; 114: 504-511
10. Schneider MP, Ge Y, Pollock DM et al. Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension 2008; 51: 1605-1610
11. Ge Y, Bagnall A, Stricklett PK et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 2006; 291: F1274-F1280
12. Ge Y, Bagnall A, Stricklett PK et al. Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol 2008; 295: F1635-F1640
13. Ge Y, Stricklett PK, Hughes AK et al. Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Renal Physiol 2005; 289: F692-F698
14. Inscho EW, Imig JD, Cook AK et al. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol 2005; 146: 1019-1026
15. Schneider MP, Inscho EW, Pollock DM. Attenuated vasoconstrictor responses to endothelin in afferent arterioles during a high-salt diet. Am J Physiol Renal Physiol 2007; 292: F1208-F1214
16. Plato CF, Pollock DM, Garvin JL. Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol Renal Physiol 2000; 279: F326-F333
17. Herrera M, Hong NJ, Ortiz PA et al. Endothelin-1 inhibits thick ascending limb transport via Akt-stimulated nitric oxide production. J Biol Chem 2009; 284: 1454-1460
18. Stuart D, Rees S, Woodward SK et al. Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol 2012; 13: 166
19. Nakano D, Pollock DM. Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension 2009; 53: 324-330
20. Lynch IJ, Welch AK, Kohan DE et al. Endothelin-1 inhibits sodium reabsorption by ETA and ETB receptors in the mouse cortical collecting duct. Am J Physiol Renal Physiol 2013 May 22. [Epub ahead of print]
21. Rebibou JM, He CJ, Delarue F et al. Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992; 7: 288-292
22. Hocher B, Thone-Reineke C, Rohmeiss P et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380-1389
23. Morigi M, Buelli S, Angioletti S et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: Implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005; 166: 1309-1320
24. Morigi M, Buelli S, Zanchi C et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006; 169: 1965-1975
25. Minchenko AG, Stevens MJ, White L et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003; 17: 1514-1516
26. Rastaldi MP, Tunesi S, Ferrario F et al. Transforming growth factor-beta, endothelin-1, and c-fos expression in necrotizing/crescentic IgA glomerulonephritis. Nephrol Dial Transplant 1998; 13: 1668-1674
27. Lehrke I, Waldherr R, Ritz E et al. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol 2001; 12: 2321-2329
28. Ohta K, Hirata Y, Shichiri M et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 39: 307-311
29. Dhaun N, Lilitkarntakul P, Macintyre IM et al. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 2009; 296: F1477-F1483
30. Iwasa S, Fan J, Shimokama T et al. Increased immunoreactivity of endothelin- 1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis 1999; 146: 93-100
31. Bacon CR, Cary NR, Davenport AP. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 1996; 79: 794-801
32. Ortmann J, Amann K, Brandes RP et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44: 974-981
33. Benigni A, Zoja C, Corna D et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440-444
34. Benigni A, Zola C, Corna D et al. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996; 27: 416-423
35. Nakamura T, Ebihara I, Fukui M et al. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995; 44: 895-899
36. Sasser JM, Sullivan JC, Hobbs JL et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007; 18: 143-154
37. Saleh MA, Pollock JS, Pollock DM. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J Pharmacol Exp Ther 2011; 338: 263-270
38. Gagliardini E, Corna D, Zoja C et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009; 297: F1448-F1456
39. Barton M, Haudenschild CC, d'Uscio LV et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998; 95: 14367-14372
40. Bussemaker E, Passauer J, Reimann D et al. The vascular endothelin system is not overactive in normotensive hemodialysis patients. Kidney Int 2002; 62: 940-948
41. Hand MF, Haynes WG, Webb DJ. Reduced endogenous endothelin-1- mediated vascular tone in chronic renal failure. Kidney Int 1999; 55: 613-620
42. Goddard J, Johnston NR, Hand MF et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation 2004; 109: 1186-1193
43. Goddard J, Eckhart C, Johnston NR et al. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004; 15: 2601-2610
44. Dhaun N, Macintyre IM, Melville V et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009; 54: 113-119
45. Dhaun N, MacIntyre IM, Kerr D et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57: 772-779
46. Humbert M, Segal ES, Kiely DG et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344
47. Hartman JC, Brouwer K, Mandagere A et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwichcultured human hepatocytes. Can J Physiol Pharmacol 2010; 88: 682-691
48. Wenzel RR, Littke T, Kuranoff S et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20: 655-664
49. Mann JF, Green D, Jamerson K et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527-535
50. Black HR, Bakris GL, Weber MA et al. Efficacy and safety of darusentan in patients with resistant hypertension: Results from a randomized, doubleblind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007; 9: 760-769
51. Kohan DE, Pritchett Y, Molitch M et al. Addition of atrasentan to renin- angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22: 763-772
52. Cross DM, Horsley E, Derzi M et al. An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats. Birth Defects Res B Dev Reprod Toxicol 2012; 95: 327-336